Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs. Late NeoProfen for PDA Closure
NCT00833365Phase 4Terminated
- Sponsor
- University of Utah
- Start
- Jan 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Ibuprofen L-lysine in patent ductus arteriosus (PDA), sponsored by University of Utah. Primary endpoint: Number of PDA Closures Related to Treatment With Ibuprofen at 48 hours. Started Jan 2009; status: terminated.
02
Drugs
Ibuprofen L-lysine
03
Conditions
patent ductus arteriosus (PDA)
Beyond the preview
Go deeper on NCT00833365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833365.